New Drug Evaluation - Opicapone for mid-to-late stage Parkinson's disease

17th May 2017

The New Drug Evaluation for Opicapone (Ongentys) for the treatment of mid-to-late Parkinson's disease with end-of-dose motor fluctuations is now online. This publication provides a concise, structured evaluation of the efficacy, safety, cost and potential place in therapy for this new product.